Boston Scientific lifts annual profit view on steady heart devices demand
Shares of the Massachusetts-based company rose 2.3% in premarket trading following the results.
A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures.
Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average.
Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter.
Farapulse, approved in the U.S. to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's (JNJ.N), opens new tab Varipulse and Medtronic's (MDT.N), opens new tab PulseSelect in the market for pulsed field ablation (PFA) systems.
"Cardiovascular end-markets remain robust," Truist analyst Richard Newitter said ahead of the earnings, adding that Boston, followed by Medtronic, are in the best position at the moment to benefit from the growing and accelerating PFA market.
Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse.
Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier.
It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG.
The company's cardiovascular unit reported quarterly sales of $3.34 billion, surpassing estimates of $3.20 billion.
Revenue came in at $5.06 billion for the quarter, topping estimates of $4.9 billion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
29 minutes ago
- Reuters
US appeals court extends suspension of 98-year-old judge in fitness probe
WASHINGTON, July 28 (Reuters) - The U.S. Court of Appeals for the Federal Circuit said on Monday that it would extend its suspension of 98-year-old judge Pauline Newman for another year after determining that she had not complied with an internal investigation into her fitness to serve on the Washington, D.C.-based court. A committee of the court's active judges determined, opens new tab that reports from doctors chosen by Newman did not eliminate the need for her to undertake "a full neuropsychological battery of tests" to ascertain whether she was capable of continuing to serve. Newman's attorney Greg Dolin said on Monday that the committee did not take sufficient time to consider their arguments, noting that the court published its 90-page opinion just days after a July 24 hearing on the suspension. "The idea that they took anything we said seriously" was "just laughable," he told Reuters. Dolin argued during the hearing that the court had enough information from several medical experts to resolve the investigation and end Newman's suspension, according to a transcript. A spokesperson for the Federal Circuit declined to comment on the ruling. Newman is the oldest federal judge not to have taken a form of semi-retirement known as senior status. Appointed to the Federal Circuit by Republican President Ronald Reagan in 1984, Newman is a respected patent jurist and a prominent dissenter at the Washington, D.C.-based court, which frequently rules on high-stakes intellectual property cases involving major companies. The Federal Circuit's chief judge, Kimberly Moore, said in orders made public in 2023 that Newman had shown signs of serious cognitive and physical impairment. The court suspended Newman later that year after finding that she had refused to cooperate with an investigation into her fitness. Newman has maintained that she is fit to serve and sued the council over her suspension. A judge dismissed her case last year, and a separate federal appeals court in Washington is currently considering whether to revive it. Newman has submitted reports from neurologists vouching for her mental fitness. The court on Monday expressed concerns about the reports' credibility, finding that they contained misstatements about her health and that her medical records contained concerns about fainting episodes and impaired memory. "The expanded record leaves no doubt that the neuropsychological testing ordered by the committee from the outset is necessary," the court said.
Reuters
29 minutes ago
- Reuters
Bristol Myers, Bain Capital form new company to develop immunology drugs
July 28 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday. The new company will work on five experimental drugs licensed from Bristol Myers, including a late-stage lupus treatment and a mid-stage psoriasis drug that has shown promise in trials. Bristol Myers will retain nearly 20% equity in the venture and is set to receive royalties and milestone payments based on the drugs' success. The collaboration allows the drugmaker to concentrate its immunology research on treatments aimed at resetting the immune system while ensuring the continued development of promising assets, the companies said. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, senior vice president of business development at Bristol Myers. Daniel Lynch, a seasoned pharmaceutical executive, will take on the roles of executive chairman and interim CEO of the new company, while Bristol Myers' chief research officer Robert Plenge is set to join the board alongside Bain Capital partners. Canada Pension Plan Investment Board also participated in the financing round.
Reuters
29 minutes ago
- Reuters
Universal Health Services beats quarterly profit estimates on higher medical care demand
July 28 (Reuters) - U.S. hospital operator Universal Health Services (UHS.N), opens new tab beat Wall Street estimates for second-quarter profit on Monday, driven by sustained demand for medical care services. Health insurers have flagged elevated demand and costs in individual Affordable Care Act (Obamacare) and Medicaid plans for low-income individuals, which could benefit hospital operators. Last week, larger peer HCA Healthcare (HCA.N), opens new tab beat quarterly profit estimates but saw its shares decline amid concerns over impending changes to Medicaid and Obamacare insurance plans under the Trump administration. Universal Health's same-facility adjusted admissions increased by 2% at acute care hospitals during the quarter, while admissions at behavioral healthcare facilities grew by 0.4%. The company now sees its 2025 revenue to be between $17.10 billion and $17.31 billion, compared to the previously expected range of $17.02 billion to $17.36 billion. Analysts, on average, expect 2025 revenue of $17.14 billion, according to data compiled by LSEG data. For the quarter ended June 30, the King Of Prussia, Pennsylvania-based company reported an adjusted profit of $5.43 per share, beating estimates of $4.92 per share. Investors are currently focused on how hospital operators will address potential tariffs affecting global supply chains for medical devices and surgical equipments. The sector is also preparing for the expiry of Obamacare subsidies next year, a change expected to impact patient coverage, raise insurance premiums and reduce enrollment numbers, potentially leaving hospitals responsible for increased uncompensated care costs.
